hGH fragment comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-14. Numbers and descriptions here follow the published literature rather than marketing material.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
| Property | Value | Notes |
|---|---|---|
| Common name | AOD-9604 | Development code used in scientific literature. |
| Chemical class | Synthetic peptide | Fragment of human growth hormone. |
| Amino acid length | 16 residues | Matches hGH region 176-191. |
| Appearance | White to off-white powder | Typical lyophilized peptide solid. |
| Solubility | Soluble in water | Dissolves in aqueous media; exact behavior depends on salt form. |
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
== Selected awards == From 1981 member of the European Molecular Biology Organization (EMBO). From 1982 honorary member of the American Society for Biochemistry and Molecular Biology. Received the Arrhenius Medal in 1983. From 1985 member of the Protein Society, USA. 1985 he was awarded two highly esteemed international scientific prizes given every second year, covering different major areas in biotechnology/biochemistry) as listed below: In Enzyme Engineering by the Engineering Foundation, New York, USA, "in recognition of outstanding contributions to the field of enzyme engineering".(previous winners: Dr. Chibata, subsequent to him Professors Katchalski-Katzir, Fukui, Klibanov, Lilly, Kula/Wandrey (jointly)). For "important contributions in the field of affinity chromatography" by the International Organization on Affinity Chromatography and Biorecognition (first winner K. Mosbach followed by M. Wilchek (1989), C.R. Lowe (1991), I.M. Chaiken (1993), J. Porath (1995), Regnier/Uhlén (1997) (jointly), Kasai (1999) and Vijayalaksmi (2001)... In 1990 he was awarded the gold medal of the Royal Swedish Academy of Engineering Sciences for his contribution to biotechnology, especially on the immobilization of bioactive substances. In 1993 he was awarded the research prize by the Swedish Fund for "Research without Animal Experiments". In April 1999, Biogen Inc., together with its early members including Klaus Mosbach, received the US National Gold Medal of Technology. The recipient of this award was selected by the Department of Commerce and presented by the president William J.
== ST == st – (s) Sotho language (ISO 639-1 code) ST (s) Saint Lucia (FIPS 10-4 country code) São Tomé and Príncipe (ISO 3166 digram) STA (i) Scheduled Time of Arrival Surveillance and Target Acquisition STAGE – (a) Scenario Toolkit And Generation Environment STANAG – (p) (NATO) Standardisation Agreement STAR (a) Scientific and Technical Aerospace Reports (NASA) Simulation of Tactical Alternative Responses Special Threat Analysis and Recognition STAT (a) Signal Transducers and Activators of Transcription (cell biology) Special Tertiary Admissions Test (Australia) STB - Surface Transportation Board STC – (i) Superior Temporal Cortex S&TCD – (i) CERDEC Space and Terrestrial Communications Directorate STD (s) São Tomé and Príncipe dobra (ISO 4217 currency code) (i) Sexually Transmitted Disease STDM – (i) Statistical Time Division Multiplexing STEM (a) Scanning transmission electron microscopy Science, technology, engineering, and mathematics (p) Spatiaotemporal Epidemiological Modeler (IBM-developed software) STENTOR – (p) Satellite de télécommunications pour expérimenter de nouvelles technologies en orbite (French, "Orbital New Technology Experimental Telecommunications Satellite") STFU (i) Southern Tenant Farmers Union Stuff You "Shut the fuck up!" STH – Sonic the Hedgehog STI (i) Sexually Transmitted Infection Subaru Tecnica International STK – (i) Satellite Tool Kit STM – (i) Short Term Memory STOL – (i) Short Take-Off and Landing STOVL – (i) Short Take-Off and Vertical Landing STP (s) São Tomé and Príncipe (ISO 3166 trigram) (i) Standard Temperature and Pressure STR – (i) Short Tandem Repeat (DNA analysis) STRATCOM – (p) United States Strategic Command STRICOM (p) U.S. Army Simulation, Training & Instrumentation Command (1992–) Strike Command (1962–1971) STRIVE – (a) Synthetic Tactical Real-time Interactive Virtual Environment STSM – (i) Senior Technical Staff Member Stuka – (p) Sturzkampfflugzeug (German WWII dive bomber)
== Geology == The depression filled by Lake Afdera was formed by faults oriented in several directions linking the Erta Ale Volcanic Range, the Tat'Ali volcanic range, and Alayta volcanic range. Furthermore, a circular depression in the southern basin is interpreted to possibly represent a volcanic caldera.
=== Post-release === The retail version included new content, such as three additional weapons designed by Minh Le and updated player models provided by Valve. Maverick Developments created a training map for the retail edition. On November 9, 2000, Valve announced that the retail version had gone gold, and the mod version was released shortly after. It was launched under the name Half-Life: Counter-Strike because according to Jess Cliffe, the game did not have a strong identity. After launch, Valve continued releasing updates. Version 1.1 implemented a new spectator mode, version 1.3 introduced voice chat, and version 1.4 added anti-cheat measures. Counter-Strike 1.5, released on June 12, 2002, was the last update before transitioning to Steam. In October 2002, it was stated that Counter-Strike 1.6 would initially be distributed via Steam, with a beta test preceding its official release. Public beta testing was originally set to begin in mid-November, but the launch was first postponed to mid-December before finally starting on January 16, 2003. On the same day, due to overwhelming demand, further beta admissions were quickly suspended as Steam's servers ran out of bandwidth. It was available to the public once again in July 2003. Along with the beta release, Valve and Plantronics announced a blue-and-gold-colored Counter-Strike headset based on Plantronics' DSP-500 headset. The headset had an adjustable microphone boom, a built-in volume control, and was usable with a USB port rather than a sound card.
Sources: en.wikipedia.org
It was thus becoming increasingly evident that the alternative of "democratic rupture" accompanied by "decisive national action" was not viable, so its main supporter, the Communist Party of Spain, decided in March 1976 to change strategy and adopt the alternative of "agreed democratic rupture" advocated by the moderate opposition and the PSOE ─ which had formed the Democratic Convergence Platform ─ although without abandoning the mobilization of citizens to exert continuous pressure on the government and force it to negotiate with the opposition. The change of strategy of the PCE, allowed the merger on March 26 of the two unitary organizations of the opposition, the Junta Democrática and the Plataforma de Convergencia Democrática, which led to the creation of Coordinación Democrática ─ popularly known as Platajunta. In its first manifesto, it rejected the "Arias-Fraga reform" and demanded an immediate political amnesty, full trade union freedom and a "rupture or democratic alternative through the opening of a constituent period". Thus, from the first scenario of rupture with popular uprising, the demand for the calling of general elections from which a constituent process could be derived. Shortly after the Platajunta was formed the government tolerated the socialist trade union Unión General de Trabajadores (UGT) to hold inside the country its XXX Congress camouflaged under the term Jornadas de Estudio (Study Days), but at the same time the police arrested the leader of CC OO, Marcelino Camacho.
=== Clinical guidelines for preventing pressure ulcers === Numerous evidence-based and expert consensus-based clinical guidelines have been to developed to help guide medical professionals internationally and in specific countries including the UK. The Standardized Pressure Injury Prevention Protocol (SPIPP) Checklist is a derivative of the International Guideline that was designed to facilitate consistent implementation of pressure injury prevention. In 2022, United States Congress passed legislation updating the Military Construction and Veterans Affairs and Related Agencies Appropriations Act, 2015 (H.R. 4355) to establish the SPIPP Checklist as law that United States Department of Veterans Affairs (VA) facilities should adhere to in order to keep patients safe from harm.
This will allow healthcare professionals to digitally track the immunization status of beneficiaries (mother and children) on a real-time basis and address the vaccination needs immediately. Doctors and medical professionals may soon be able to manage appointments and maintain patient records over the vaccine platform CoWIN, with the National Health Authority (NHA) integrating it with the Ayushman Bharat Digital Health Mission (ABDM)—the backbone of India's digital healthcare system. This lightweight health management information system (HMIS) solution will allow small clinics and providers to manage appointments, patient information and prescriptions. The HMIS will be integrated with all ABDM modules and allow the doctor and clinic to create a health professional ID and a health facility ID.
Sources: en.wikipedia.org
Aldehydes are the natural by-product of many physiological processes, as well as being the consequence of many industrial processes, put out into the environment in the form of smog and motor vehicle exhaust. Build-up of aldehydes in the brain and pericardium can be detrimental to a person's health, as they can form adducts with important molecules and cause their inactivation. Considering how prevalent aldehydes are, there must be an enzyme to facilitate their oxidation to a less volatile compound. Aldehyde dehydrogenases (ALDH) are NAD+ dependent enzymes that function to remove toxic aldehydes from the body, functioning mostly in the mitochondria of cells. These enzymes are largely responsible for the detoxification of acetylaldehyde, which is an intermediate in the metabolism of ethanol. It has been shown that a mutation in the ALDH2 gene (one of 19 aldehyde dehydrogenase genes) is what leads to the common occurrence in East Asian population of a flushed face after consuming alcohol, due to the build-up of acetaldehyde. This build-up of acetaldehyde also causes headaches and vomiting (hangover symptoms) if not broken down quickly enough, another reason why those with acetaldehyde DH deficiencies have bad reactions to alcohol. Importantly, a lack of this enzyme has been linked to an increase in the risk of myocardial infarction, while activation has shown the enzyme's ability to reduce damage caused by ischaemia. Deactivation of aldehyde dehydrogenases has been shown to be instrumental in the mechanisms of many cancers.
=== Acoustic lysis === This method uses ultrasonic waves to generate areas of high and low pressure which causes cavitation and in turn, cell lysis. Though this method usually comes out clean, it fails to be cost effective and consistent.
express the short-range order of the liquid, i.e., the correlations between a molecule and "shells" of nearest neighbors, next-nearest neighbors, and so on. An equivalent representation of these correlations is the radial distribution function
== Preparation == The highly basic character of caricain makes it relatively easy to separate from the other papaya cysteine endopeptidases in cation-exchange chromatography of preparations of commercially available papaya latex. A sodium acetate gradient, pH 5.0, was first used successfully by Robinson and has since been adopted by others. Caricain is found in the latest-eluting protein peak. Due to the charge heterogeneity of caricain the peak may not be symmetrical, but this does not necessarily indicate the presence of contaminants. Covalent chromatography on thiol-Sepharose allows isolation of fully active caricain from the material obtained by cation exchange.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.
No. It contains only a small portion of the human growth hormone sequence. The full hormone has 191 amino acids and many additional actions that the fragment does not share.
The name refers to the amino acid positions in the human growth hormone chain. The fragment spans residues 176 through 191 at the C-terminal end. This naming convention helps distinguish it from full-length hGH.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.